Tonix Pharmaceuticals announces acquisition of Healion Bio antiviral portfolio Transcript
Welcome to our Proactive Studios. I'm Natalie Stoberman, joined by the CEO of Tonix Pharmaceuticals. Seth Lederman. Seth, thank you for joining us again.
Thank you for having me [on].
Questions & Answers
It's my pleasure, especially when there's big news on the table like an acquisition, what are the details of the company's acquisition of Healion Bio?
We bought Healion because it has really interesting, broad spectrum antiviral technology. And there's a history between our Head of Infectious Disease Research, Sina Bavari, and Healion. Sina Bavari was a Co-Founder of Healion and in fact, the Scientific Founder of Healion. He did that after he left his position as Head of R&D at the United States Army Medical Research Institute for Infectious Disease, which is called USAMRIID
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
